Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients
900 views · Published 16 November 2015 · 10:16 · Indexed 29 October 2026
Channel: American Society of Hematology · 2015 · Nonprofits & Activism
The anti-CD38 monoclonal antibody daratumumab had a favorable safety profile with manageable infusion-related reactions, according to results from a phase 2 study of multiple myeloma patients who had been treated with three or more prior therapies. Peter M. Voorhees, MD, discusses the results.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding